The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U.K. A retrospective cohort analysis of a primary care database in the U.K. was carried out. Patients with chronic montelukast use (140 once-daily doses) were selected for analysis. Benchmarking data were obtained for matched patients with chronic inhaled corticosteroid (ICS) use and patients with chronic salmeterol therapy with concomitant ICS use. The main outcome measures were changes in utilization and monthly cost of asthma therapies costs. Asthma patients experienced significant (P50?05) reductions in the monthly costs of ICS, short-acting b-agonists and antibiotics following chronic montelukast therapy. Monthly concomitant drug costs were reduced by £7?49 per month, which offset 27?5% of the additional cost of montelukast, yielding an increase in total drug costs of £19?78 per month. Meanwhile, increased total drug costs for matched patients with chronic ICS use, and matched patients with chronic salmeterol therapy and concomitant ICS use, increased by £5?37 per month and £44?55 per month respectively. Additionally, patients using chronic montelukast therapy experienced a statistically significant (P50?05) reduction in the use of short acting b-agonists, and antibiotics, suggesting improvement in asthma control.
Introduction
Asthma is a chronic disease of the airways that currently afflicts over 100 million people worldwide, and constitutes a serious public health problem in countries throughout the world (1) . Because of its high prevalence and significant morbidity, asthma represents a tremendous economic burden to society both in the direct costs of medical treatment, including hospitalization and doctor's visits, as well as indirect costs due to lost productivity. In the U.K., the total annual cost of asthma (indirect and direct) is estimated to be £322 million (2) . It has been estimated that three quarters of the total cost of asthma is related to hospitalization, emergency admission and lost productivity at work or school resulting from poor asthma control (3) . Thus, improving control has the potential to greatly reduce the economic burden of this disease.
Leukotriene receptor antagonists, a new class of oral asthma controlling medications, have been recently introduced in the U.K. In clinical trials, the leukotriene receptor antagonist montelukast improved asthma control when used alone or with concomitant inhaled corticosteroids (ICS) (4) (5) (6) (7) . Use of montelukast may also facilitate reductions in ICS dosage and b-agonist use (8, 9) . Therefore, physicians who use montelukast may change their prescribing patterns and attempt to reduce the use of such concomitant asthma therapies.
The purpose of this study was to assess prescribing patterns of GPs by estimating changes in the per patient costs of asthma medications following chronic use of montelukast therapy. To provide benchmarking information, changes in asthma drug therapy costs for matched patients receiving chronic inhaled corticosteroids (ICS) and matched patients with chronic use of salmeterol, a longacting b-agonist, with concomitant ICS use were also evaluated. The study was based on a retrospective analysis of data from a cohort of asthma patients in the U.K.
Methods
Drug utilization data were obtained from the U.K. Mediplus 1 database. This database contains diagnosis and prescribing information on more than one million patients from a nationally representative sample of 545 GPs. The database was searched from 1 February 1997 to 28 February 1999. Adult patients (older than 14 years of age) with chronic use of asthma therapy and one of the following computer recorded diagnoses were included in the analysis: asthma, extrinsic asthma, intrinsic asthma, status asthmaticus, or asthma attack. Patients with computer recorded diagnoses of chronic obstructive pulmonary disease, chronic bronchitis, or emphysema were excluded.
To assess changes in asthma drug utilization associated with chronic use of montelukast therapy, data were obtained for at least 140 days before and after each patient's first montelukast prescription. The date of the first montelukast prescription was defined as the index prescription date (IPD). Chronic montelukast therapy was defined as at least 140 once daily doses within 6 months following the IPD. The length of the patients' montelukast therapy was estimated as the number of days from the IPD to the last montelukast prescription date plus the number of montelukast daily doses supplied by the last prescription. The time period of analysis before the IPD was the same as the length of the patients' montelukast therapy. All patients who met the above criteria were evaluated, regardless of concomitant asthma therapy.
To obtain benchmarking information, two additional groups were analysed by one-to-one matching of patients in each group to montelukast patients. To ensure that patients can be classified into only one group the following scheme was utilized: (i) chronic ICS use without montelukast (patients with three or more ICS prescriptions following the IPD of the matching montelukast patient); and (ii) patients using chronic salmeterol treatment with concomitant ICS (patients with five or more salmeterol prescriptions starting within 30 days of the date of the matching montelukast patient's IPD). As salmeterol is not licensed for first line therapy in the U.K., salmeterol patients were also required to have at least one ICS prescription after the initiation of salmeterol treatment. It was estimated that an ICS prescription could last up to approximately 1?5 months, and that a salmeterol prescription could last up to 1 month. Thus, the cutoff points requiring three prescriptions for the ICS cohort and five prescriptions for the salmeterol cohort after the IPD were chosen as they were considered sufficient to indicate chronic use of therapy in the 5-6 months following the IPD. As few salmeterol initiations are likely to occur on the same day within the matching criteria set, we allowed +1 month to enable sufficient recruitment, but not so broad as to allow major seasonal factors to affect the data. For evaluation purposes, the IPD for each ICS patient was defined to be the same as the IPD of the matching montelukast patient; and for salmeterol patients, the IPD was defined as the date of salmeterol initiation. Patients were matched based on gender, age (+5 years), the length and dates of asthma therapy, and asthma severity, requiring matched patients to have had the same number of prescriptions (+1) for short acting b-agonist for the 3 months before each patient's IPD (Fig. 1) .
Monthly use of the following asthma drugs was evaluated: ICS, long-acting b-agonists, short-acting b-agonists and antibiotics. Drug use was assigned monetary value by means of the per pack pharmacy purchase price for each specific brand or generic drug prescribed obtained from contemporaneous issues of the British Pharmaceutical FIG. 1. Scheme for matching chronic montelukast patients with patients using chronic ICS and patients using chronic salmeterol with concomitant ICS use. 1 Same number (+1) prescriptions for short-acting b-agonists in 3 months before the IPD.
2 Index Prescription Date. 
Results
There were 68 861 asthma patients in the database, of whom 189 patients were found to have been initiated on montelukast. Only 94 patients, however, met the inclusion criteria of having already received at least 140 once daily doses within 6 months and, of these, 89 were able to be matched to chronic ICS patients and were included in the study. Forty-nine of the patients having chronic salmeterol use with concomitant ICS use met the inclusion criteria and could be matched to chronic montelukast patients and included in the analysis. The matched groups' average number of short-acting b-agonist prescriptions during the 3 months prior to the IPD did not differ among groups (Table 1) . Patients in both montelukast groups received higher levels of concomitant asthma drug therapy than their respectively matched patients in the ICS and salmeterol groups (Tables 2 and 3 ). Of the 89 montelukast patients matched with ICS 44?9% and 87?6% used concomitant salmeterol or ICS, respectively, after the IPD. Of the 49 montelukast patients matched with salmeterol 49?4% and 85?7% used concomitant salmeterol or ICS, respectively, after the IPD.
Patients in the montelukast cohort experienced significant reductions (P50?05) in the monthly costs of ICS, short-acting b-agonists and antibiotics following chronic use of montelukast therapy. The total reduction of nonmontelukast drug costs was £7?49 per month. This cost reduction offset the £27?27 per month additional cost of monetelukast by 27?5%, resulting in net additional drug costs associated with montelukast use of £19?78 per month. In addition, chronic montelukast patients experienced significant reductions (P50?05) in the number of packs of short-acting b-agonists and antibiotics prescribed, and a non-significant reduction (P40?05) in packs of oral steroids prescribed (Table 2) .
Matched patients using chronic ICS treatment experienced significant (P50?05) increases in the monthly costs of ICS over the same time period as their matched chronic montelukast patients. The total drug costs for matched chronic ICS patients increased by £5?37 per month over costs before the IPD. In addition, matched chronic ICS patients experienced a significant increase (P50?05) in the number of packs of short-acting b-agonists, but nonsignificant reductions (P40?05) in the number of packs of antibiotics and oral steroids prescribed after the IPD (Table 2) .
Patients with chronic salmeterol use and concomitant ICS use experienced a significant increase (P50?05) in the monthly costs of ICS following initiation of salmeterol. Including the cost of salmeterol, the total drug costs for these patients increased by £44?55 per month over costs before the IPD. Meanwhile, patients with chronic montelukast use matched to these salmeterol patients experienced significant reductions (P50?05) in the monthly costs of short-acting b-agonists and antibiotics following initiation of therapy. Including the cost of montelukast, the total drug costs for the matched chronic montelukast patients increased by £22?76 per month. Chronic salmeterol patients with concomitant ICS use experienced a non-significant reduction (50?5%) (P40?05) in the number of short- acting b-agonist inhalers prescribed, but there were nonsignificant (P40?05) increases in the number of prescriptions for antibiotics and oral steroids after the IPD. In contrast, matched chronic montelukast patients experienced a significant reduction (P50?05) in the number of packs of antibiotics prescribed, and non-significant reductions (P40?05) in the number of packs of short-acting b-agonists and oral steroids prescribed (Table 3) .
Discussion
Primary care physicians in the U.K. have restricted prescribing budgets. This may limit their willingness to use new therapies which appear to be superficially expensive. This study provides prescribing cost data that is necessary for those making decisions about prescribing costs including cost-conscious physicians. This real world data about prescribing patterns associated with chronic use of montelukast during its first year of use supplies such information. Consequently, sample sizes are small with only 189 patients commenced on montelukast within the first year due to initial low prescribing.
The results indicate that chronic use of montelukast is associated with a significant reduction in the costs of concomitant asthma drug therapy. Patients using chronic montelukast therapy were found to have statistically significant reductions in the monthly costs of ICS, shortacting b-agonists and antibiotics following initiation of therapy. The reductions in concomitant drug costs provided a partial offset of the cost of montelukast for these patients.
It is important to benchmark such data as far as possible by using comparator patients matched as far as possible to take account of any confounding factors. One confounding factor that is difficult to remove is the different knowledge and skills of the prescribing physician. The study provides benchmarking information about matched patients receiving chronic ICS therapy and matched patients receiving chronic salmeterol therapy with concomitant ICS. Patients were matched to patients on montelukast for severity based upon use of short-acting b-agonists before the IPD. The results show an increase in the costs of drug therapy in all the study groups. This suggests that physicians prescribed montelukast to patients they considered in need of additional therapy and that the matching algorithm identified patients who probably needed additional therapy in the two benchmarking groups. Indeed, the results show that physicians increase their prescribing of asthma medications to patients in the two benchmarking groups.
This was a retrospective study and thus limited by the characteristics of the database. All hypotheses were made a priori, however, and participant and selection biases that can occur in prospective clinical studies did not exist. The results of this study were limited to those patients with chronic use of montelukast and therefore cannot be extrapolated to patients with intermittent use or those who initiate but discontinue therapy. Because the database contained only information on prescriptions, the study was limited to calculating drug costs, with no measure of other direct and indirect costs associated with asthma. Moreover, since no measure of effectiveness was available, costeffectiveness determinations were impossible to make.
While attempts to match demographics, seasonal effects and asthma severity among patient groups were as diligent as possible, there may have been differences between patients that the database was not able to portray, such as differences between the characteristics of patients receiving each treatment. Indeed, assessment of prescribing patterns before the IPD shows higher consumption of asthma drug therapies by patients in the two montelukast groups than their respectively matched patients.
Changes in prescribing patterns are particularly interesting for the 49 patients who were matched to the patients initiated on salmeterol. Both patients groups required an initiation of additional asthma therapy, salmeterol or montelukast, and were matched for severity on levels of short-acting b-agonists prescriptions before IPD. However, cost of asthma drug therapy before IPD was much higher among patients who received montelukast than among patients who received salmeterol resulting in similar monthly costs at the end of the study for both groups (60?07 and 61?12). This shows that during the first year of montelukast usage in the U.K., when prescribing montelukast, the physicians reduced their prescribing of concomitant asthma therapies. When prescribing salmeterol the physicians increased their prescribing of concomitant asthma therapies. This may suggest that patients on high levels of asthma therapy who started montelukast could achieve an improvement in asthma control as measured by reductions in the use of short-acting b-agonists, antibiotics and oral steroids at a comparable cost of prescribing salmeterol.
There may also have been differences in the prescribing patterns of physicians. Physicians who prescribed montelukast may have been aware of the published clinical studies suggesting that montelukast may enable ICS tapering. While this would explain the reduction in the cost of ICS, it cannot account for the reductions in packs of short-acting b-agonists and antibiotics prescribed.
The concomitant drug cost reductions of £7?49 per month for chronic montelukast patients do not appear to be the result of seasonal differences. Matched patients on chronic ICS over the same time period experienced an increase in total asthma drug costs of £5?37 per month. Assuming the montelukast and matched patient groups are comparable, combining the £7?49 per month cost reductions associated with use of chronic montelukast therapy with the £5?37 per month cost increase associated with chronic ICS therapy would yield a total expected savings of £12?86 per month in non-montelukast drug costs for chronic montelukast therapy, as compared with chronic ICS therapy in patients with asthma that in retrospect merited an increase in asthma therapy. This amount would offset 47?2% of the monthly cost of montelukast, resulting in a net additional cost for chronic montelukast use of £14?41 per month.
Clinical studies have reported that the effectiveness of chronic salmeterol therapy may be partially limited by tolerance that has been observed within 4 weeks of continued use (11, 12) . Patient tolerance to chronic montelukast therapy has not been observed in clinical studies with durations of up to 2?4 years (4-6,9,13). Patients with chronic use of salmeterol therapy did not appear to experience improvement in asthma control over the 6 month duration of this study, as measured by the consumption of short-acting b-agonists, antibiotics and oral steroids. Moreover, while similar monthly costs were observed for both groups at the end of the study, the total increase in monthly drug therapy costs for chronic salmeterol patients was £21?79 pounds per month more than that for matched chronic montelukast patients.
The study evaluates changes in prescribing patterns and is not intended to provide information about the relative effectiveness of the different therapeutic approaches evaluated. While there were no measures of effectiveness, the study chose, as a surrogate of asthma control, to assess the change in the average number of packs prescribed for three medications: oral steroids, often prescribed as emergency treatment in hospitals; antibiotics, often prescribed to treat infections; and short-acting b-agonists, commonly used for relief of asthma exacerbations. Patients dispensed more than eight b-agonist prescriptions per year have been found to have a hospitalization risk four times that of patients dispensed no b-agonists (14) . Patients on chronic montelukast therapy experienced reductions in the average number of packs of all three medications prescribed, with the reduction being statistically significant for both short-acting b-agonists and antibiotics. These results suggest that use of chronic montelukast therapy improves control of patients' asthma. The results are consistent with previous clinical studies of montelukast. Compared to placebo therapy, montelukast treatment was less likely to be associated with b-agonist rescue therapy (5) . Additionally, studies have demonstrated that montelukast use allows the tapering of ICS dosage while maintaining or increasing asthma control (8) .
Improving asthma control may require additional therapy and, therefore, increased drug costs, however, it is likely that cost reductions in other areas, including hospitalization and lost productivity, may more than offset these increases (15, 16) . A review of nine cost-ofillness studies throughout the world has indicated that drug costs represent approximately 37% of the direct costs of asthma (3). Previous cost-effectiveness studies of ICS have demonstrated that improvement of asthma control can markedly reduce non-drug costs (17, 18) . Since the results suggest that chronic montelukast use may improve asthma control, there may be additional direct cost savings associated with chronic montelukast treatment that are not reflected in this study. These potential additional savings may further offset the cost of montelukast or result in net savings.
Whilst registration trials reveal effectiveness of new pharmaceuticals in tightly controlled circumstances and patients who meet study entry criteria it is important to look at their impact on costs and effectiveness in clinical practice. Use of large primary care databases is one method of providing such data (19) in advance of data from pragmatic or 'real-world' clinical trials-although database information only reveals limited information about effectiveness as measured by relief and emergency drug treatment.
CONCLUSION
This study demonstrated that chronic montelukast therapy resulted in a reduction in the costs of concomitant asthma drug therapy, which offset a portion of the monthly cost of montelukast. This study was limited to evaluating only the cost of drug therapy; however, montelukast may potentially reduce other costs associated with asthma, both direct and indirect. Further studies elucidating the cost-effectiveness of montelukast are warranted. 
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